Spruce Biosciences

Harbour BioMed has increased its ownership in Spruce Biosciences to approximately 3.8%, marking a deeper strategic alliance beyond a traditional licensing agreement. This move underscores Harbour BioMed’s confidence in Spruce’s SPR202 antibody therapy and their collaborative efforts to accelerate novel antibody treatments for conditions like congenital adrenal hyperplasia. The expanded partnership signifies a shared commitment to bringing innovative therapies to patients.